Product Details

RenuTend suspension for injection for horses

• MA holder: Boehringer Ingelheim Vetmedica GmbH
• VM number: EU/2/22/282/001
• Territory: Northern Ireland
• Associated documents:
  • Available from EU Union Product Database
• Date of issue: 19/04/2022
• Authorisation route: Centralised
• Active substances:
  • Tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells (tpMSCs)
• Controlled drug: No
• Target species:
  • Horses
• Distribution category: POM-V